Call for Abstract

11thWorld Congress on Precision and Personalized Medicine, will be organized around the theme “Therapeutic approaches and New diagnostic technologies to Personalized Medicine”

Personalized Medicine Congress 2019 is comprised of 22 tracks and 92 sessions designed to offer comprehensive sessions that address current issues in Personalized Medicine Congress 2019.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Drug discovery and development together are the complete process of identifying a new drug and bringing it to market. Discovery may involve screening of chemical libraries, identification of the active ingredient from a natural remedy or design resulting from an understanding of the target. Development includes studies on microorganisms and animals, clinical trials and ultimately regulatory approval.

  • Track 1-1Drug Discovery
  • Track 1-2Pre-clinical Trials
  • Track 1-3Clinical Trials
  • Track 1-4FDA approval

The concept of precision medicine, in which health care is individually customized on the basis of a person's genes, lifestyle and environment. Transfusion patients have been matched with donors according to blood type for more than a century. But advances in genetics, and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality.

 

  • Track 2-1Precision Medicine Initiative
  • Track 2-2Advancing Precision Medicine
  • Track 2-3Human genome
  • Track 2-4Pioneering pharmacogenetics

Precision medicine aims to provide the right treatment for the right patient at the right time with treatment directed on the basis of the targetable tumoral aberrations rather than just a traditional histologic subtype. However to facilitate this approach, clinicians require patient derived samples. Prostate cancer is challenging to culture in vitro. Recent development of novel organoid in vitro culture technology has led to the development of multiple new in vitro prostate cancer cell line models. We aim to apply organoid culture technology to develop novel in vitro prostate cancer cell line models and propagate patient derived samples to allow drug testing and next generation sequencing as part of a precision medicine approach to early recurrent prostate cancer.

 

  • Track 3-1Invitro Organoid Technology
  • Track 3-2Digital Health
  • Track 3-3Single-Cell DNA Analysis
  • Track 3-4Progress and Challenges in Precision Medicine

Personalized Medicine Meeting  is to develop routine of medication that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, determination, and treatment of ailment. Information of a patient's hereditary profile can offer specialists some assistance with selecting the best possible prescription or treatment and manage it utilizing the correct measurement or regimen. Utilized for the treatment as Personalized growth solution, Diabetes-related sickness: hazard appraisal and administration, Personalized pharmaceutical: New procedures and monetary ramifications, Implications of customized prescription in treatment of HIV, Applications of customized drug in uncommon illnesses, Translational Medicine.

 

  • Track 4-1Applications in treating rare diseases
  • Track 4-2New born screening & prenatal testing
  • Track 4-3Development of personalized genetic medicine
  • Track 4-4Implications of personalized medicine in treatment of HIV

 Personalised medicine turns this approach on its head. It recognizes that complex diseases should no longer be considered as a single entity. One disease may have many different forms, or ‘subtypes’, resulting from the complex interaction of our biological make-up and the diverse pathological and physiological processes in our bodies. These will not only vary between patients who have the same disease but also within an individual patient as they get older and their body changes. As we integrate and analyses genomic and other data, we can find common factors and causes of variation, resulting in the discovery of new pathways of disease, changing how diseases are thought of and treated. It enables us to recognize that the same underlying change in our DNA or genome can lead to problems in very different parts of the body, which would not have been previously identified with a more traditional care approach.

 

  • Track 5-1Scope of Personalized Medicine in Present day Medicine
  • Track 5-2Key Players in the Development of Personalized Medicine
  • Track 5-3A new targeted treatment approach
  • Track 5-4Prediction and prevention of disease

The role of predictive pathology or the accurate assessment of morphology at the microscopic level. In breast cancer, this has been most useful where histologic attributes such as the classification of tubular and cribriform carcinomadictates surgery while neoadjuvant studies suggest that patients with lobular carcinoma are not likely to benefit from chemotherapy. The next level of 'personalized pathology' at the tissue-cellular level is the use of 'protein biomarker panels' to classify the disease process and ultimately drive tumor characterization and treatment. Precision pathology will focus on the evolution of predictive pathology from a subjective, 'opinion-based' approach to a quantitative science. The individual components of the precise pathology platform including advanced image analysis, biomarker quantitation with mathematical modeling and the integration with fluid-based (i.e. blood, urine) analytics as drivers of next generation precise patient phenotyping.

  • Track 6-1Breast Cancer
  • Track 6-2Novel companion diagnostics
  • Track 6-3Molecular Diagnostic Techniques

In drug, a biomarker and sub-nuclear markers is the quantifiable pointer of the reality or region of some disease state. All the more overall it is anything that can be used as a marker of a particular illness state or some other physiological state of a living being Medication Symptomatic Co-Improvement. In the present time of stratified arrangement and biomarker-driven medications, the inside has moved from figures considering the customary anatomic orchestrating systems to coordinate the choice of treatment for an individual patient to a planned strategy using the inherited beautifiers of the tumor and the genotype of the patient. Genomics and different developments have, all things considered, Personalized Medicine Congress 2018 added to the unmistakable verification and the change of biomarkers, for example, Stratification biomarkers in modified pharmaceutical.

  • Track 7-1Drug demonstrative co-improvement
  • Track 7-2The Micro biome - A modifiable biomarker?
  • Track 7-3Biomarkers to clinical diagnostics
  • Track 7-4Accurate diagnostic tests
  • Track 7-5Successful personalized medicine research programs

Precision Medicine in Oncology is doled out to illuminating, instructing, and encouraging the trading of clinically pertinent data with respect to the disclosure and utilization of new Drug regimens, Molecular biomarkers, Cancer genomics, Molecular growth and Diagnostics in strong tumors and hematologic malignancies, and in addition their effect on oncology watch over patients. Over late decades Cancer investigate has found an incredible and personalized medication to tumor research and treatment.

  • Track 8-1Screening of Oncology
  • Track 8-2Tumor DNA Sequencing
  • Track 8-3Sub-atomic Cancer
  • Track 8-4Molecular Profiling

Healthcare and medical research are generating more and more complex data, encompassing clinical investigations, genomic medicine, imaging, pharmacokinetics, metabolomics, epidemiology and beyond. This “Data Science” can form the basis for precision medicine, approaching disease prevention and treatment by taking into account individual variability in genes, environment, and lifestyle. By deeply profiling individual patients and using this to improve predictive models of pathology in individual patients, advances will be made in elucidating of the drivers of the disease and making precise targeted treatments, providing the right treatment to the right patient at the right time. Both biologists and clinicians need to understand this emerging and highly translational approach.

  • Track 9-1Data collection for eHealth and mHealth
  • Track 9-2Data and decision support in clinic
  • Track 9-3Integrative and systems analysis of disease

Preventive Medicine is sharpened by all specialists to keep their patients sound. It is also an extraordinary therapeutic distinguishing strength saw by the American Board of Medical Specialties (ABMS). Preventive Medicine focuses on the prosperity of individuals, gatherings, and portrayed peoples. It is similarly used for the treatment for strength, visual hindrance. The Epidemiology Division applies inquire about systems to fathom the illustrations and explanations behind prosperity and affliction in the people and to make a translation of this learning into ventures proposed to turn away disease. The division has a long history of consideration in NIH-bolstered multi-site, longitudinal accomplice studies, and its staff deal with various pro began, NIH-upheld investigation endeavors and trials. Open trust in antibodies is a key to the accomplishment of immunization ventures worldwide in the time of preventive solution.

  • Track 10-1Predictive testing for diverse medical conditions
  • Track 10-2Application in metabolic abnormalities
  • Track 10-3Treating ovarian cancer
  • Track 10-4Neuropsychiatric conditions: Epilepsy
  • Track 10-5Treatment of cardiovascular disease

The goal of the Personalized Medicine in cardiac research is to stimulate understanding of promising new essential examination disclosures for the treatment of heart disillusionment and arrhythmias through especially formed clinical trials that display suitability and security. Vascular Medicine encompasses an extensive variety of various sickness states. As the field of vascular Medicine builds up, the degree of ailments being managed changes. Cardiovascular revamping suggests the changes in estimate, shape, structure and physiology of the heart after harm to the myocardium. The mischief is regularly a direct result of extraordinary myocardial dead tissue. To depict the development in lipoprotein translation by hypothyroidism, adipocytes were prepared from control and hypothyroid rats. While LPL mix was higher in hypothyroid adipocytes, with no modification in mRNA levels, there was no extension in hormone-delicate lipase (HSL) mix.

  • Track 11-1Angiology
  • Track 11-2Stem cells in cardiac and vascular regeneration
  • Track 11-3Metabolic and lipoprotein translation

Immunotherapy is a type of treatment that helps the body’s immune system fight cancer. Several kinds of immunotherapy, including immune checkpoint inhibitors, adoptive cell transfer, and therapeutic vaccines are either commercially available or in clinical development. To date, six immune checkpoint inhibitors have been approved by FDA for the treatment of eight types of cancer. One of the inhibitors has also been approved to treat any solid tumor that has a specific genetic feature. This was the first FDA approval of its kind and a major advance for precision cancer medicine, in which the molecular characteristics of a tumor are used to identify effective therapies.

  • Track 12-1Immunotherapy Response, Resistance, and Toxicity
  • Track 12-2Pediatric Immunotherapy Discovery
  • Track 12-3Immuno-Oncology
  • Track 12-4Validate Immunotherapy Biomarkers
  • Track 12-5Validate Immunotherapy Biomarkers

Pharmacogenomics is a control in innate qualities that applies Recombinant DNA, DNA sequencing strategies, and bioinformatics to gathering, store up, and separate the limit and structure of genomes. Drives in genomics have set off an insurrection in exposure based examination to see even the most complex natural systems, for instance, the psyche. The field fuses attempts to choose the entire DNA gathering and human genome variety of living things and fine-scale inherited mapping. The field furthermore consolidates examinations of intragenomic wonders, for instance, heterosis, epistasis, pleiotropic and distinctive relationship amidst loci and all inside the genome and met genomics. Close genomics is an invigorating new field of regular investigation in which the genome groupings of different species human, mouse and a wide variety of various life frames from yeast to chimpanzees are contemplated.

  • Track 13-1Data solutions in clinical genomics
  • Track 13-2Metagenomics & comparative genomics
  • Track 13-3Human genome variation
  • Track 13-4Controlling outburst of mutations
  • Track 13-5Genetics informed personalized immunotherapy
  • Track 13-6Biomedical informatics

Personalized Medicine can be used to discover around a man's genetic beauty care products and to unravel the study of their tumor. Using this information, experts need to perceive reckoning, screening, and treatment procedures that may be more fruitful and cause less indication than would be ordinary with standard drugs. By performing more innate tests and examination, authorities may adjust treatment to each patient's needs. Making a tweaked harm screening and treatment game plan consolidates: Determining the chances that a man will make development and choosing screening methods to cut down the threat, Matching patients with meds that will presumably be convincing and cause less responses, Predicting the risk of rehash (return of Cancer).

  • Track 14-1Personalized medicine in organ transplantation
  • Track 14-2Cell based therapy
  • Track 14-3Controlling proliferation
  • Track 14-4Molecular mechanisms

Biospecimens contain molecules that can be analyzed for indications of diseases. Biospecimens may confirm whether a disease is present or absent in a particular person, and research on biospecimens is especially helpful for understanding more about how disease processes may start and progress. This understanding may lead to better detection of diseases at the earliest stages and may permit design of more effective treatments. Annotated human biospecimens are critical building blocks for precision medicine discovery and essential to the preclinical validation of resulting hypotheses. In this session, learn how advances in technology are improving access to a diverse range of biospecimens from patient populations and yielding increasingly useful amounts of information upon analysis.

  • Track 15-1Human Biospecimens
  • Track 15-2High Quality Bio-banking
  • Track 15-3BioSpecimen Sciences Program

Personalized drug is a field of prescription that includes anticipating the probability of disease and building up preventive measures remembering the true objective to either keep the infirmity all things considered or out and out reduction its impact upon the patient, (for instance, by maintaining a strategic distance from mortality or compelling grimness). Strategies and measures join New-conceived screening, diagnostic testing, Medical bioinformatics, Prenatal testing, Carrier testing, Preconception testing. Newborn child screening is a general prosperity program expected to screen babies not long after origination for a summary of conditions that are treatable, however not clinically clear in the baby time frame. Pre-birth testing: Prenatal testing is used to look for disorders and conditions in a hatchling or creating life before it is imagined. This sort of testing is offered for couples who have an extended peril of having a youngster with an innate or chromosomal issue. Screening can choose the sex of the incipient organism. Pre-birth testing can offer a couple some help with choosing whether to rashly end the pregnancy. Like symptomatic testing, pre-birth testing can be non-obtrusive or meddlesome. Non-prominent techniques fuse examinations of the woman's womb through ultrasonography or maternal serum screens. These non-nosy methodology can evaluate risk of a condition, however can't choose with conviction if the developing life has a condition.

  • Track 16-1Personalized medicine in healthcare
  • Track 16-2Horizons of personalized medicine
  • Track 16-3Realizing the value of personalized medicine
  • Track 16-4Bio banking: Transforming healthcare

Gene therapy is hoped to cure or improve treatment of genetic disorders by replacing the mutated or malfunctioned gene, manipulating or turning off the gene causing the disease or stimulate other bodily functions to fight the disease. The most common method is replacement of a malfunctioned or sometimes a missed gene with a healthy one. However, gene therapy poses a risk of potentially serious complications, in the first place due to the method that is used to insert the “new“ genes – the use of viruses. These have the ability to identify certain cells as well as to transmit the genetic material into the cells containing malfunctioned or missed gene. For that reason modified viruses are used as vectors or carriers of the healthy genes. This method of insertion of healthy genes may not seem problematic at a first glance but it can cause cause potentially serious complications as already mentioned earlier.

  • Track 17-1Inborn errors of metabolism
  • Track 17-2Mutations in the BRCA1and BRCA2 genes
  • Track 17-3Genetic Mutation
  • Track 17-4Enzyme replacement therapy

The goal in vaccinology is to discover, develop, and deploy highly immunogenic and safe vaccines that protect against infectious and non-infectious (i.e., cancers) diseases in essentially 100% of the population. While admirable, such a goal, to date, fails because of both pathogen and host variability. For hyper-variable viral pathogens like HIVHCVrhinovirus, and others, we have been unable to discover and develop highly immunogenic and protective vaccine candidates. This is true too for other highly complex pathogens such as bacteria (i.e., tuberculosis) and parasites (i.e., malaria). Host variability is evident in the multiplicity of immune response genes that encode >1012 products necessary for generating immune responses (i.e., antibodies, T cell receptors [TCRs], etc.), and the estimated diversity of human leukocyte antigen (HLA) haplotypes (estimated at >1013), allowing humans an almost limitless immune response capability.

  • Track 18-1Vaccinomics
  • Track 18-2Current Vaccine Development
  • Track 18-3Directed Vaccine Development
  • Track 18-4Genetic Control of Measles Vaccine Response

P4 Medicine is a course of action to significantly upgrade the idea of human life by methods for biotechnology. P4 Medicine is a term created by researcher Leroy Hood, and is another approach to state "Prescient, Preventive, Personalized Medicine, and Molecular Medicine." The reason of P4 Medicine is that, all through the accompanying 20 years, helpful practice will be modified by biotechnology, to manage a man's prosperity, instead of manage a patient's contamination. Internal arrangement or general solution (in Commonwealth nations) is the therapeutic distinguishing strength dealing with the evasion, assurance, and treatment of adult illnesses. Emergency arrangement is a restorative distinguishing strength including watch over adult and pediatric patients with extreme infections or wounds that require speedy remedial thought.

  • Track 19-1Personalized medicine & targeted therapeutics
  • Track 19-2Companion diagnostic market
  • Track 19-3Strategic analysis of industry trends
  • Track 19-4New strategies & economic implications

Metabolomics, which is defined as the comprehensive analysis of metabolites in a biological specimen, is an emerging technology that holds promise to inform the practice of precision medicine. Historically, small numbers of metabolites have been used to diagnose complex metabolic diseases as well as monogenic disorders such as inborn errors of metabolism. Current metabolomic technologies go well beyond the scope of standard clinical chemistry techniques and are capable of precise analyses of hundreds to thousands of metabolites. Consequently, metabolomics affords detailed characterization of metabolic phenotypes and can enable precision medicine at a number of levels, including the characterization of metabolic derangements that underlie disease, discovery of new therapeutic targets, and discovery of biomarkers that may be used to either diagnose disease or monitor activity of therapeutics.

  • Track 20-1Emerging applications of metabolomics
  • Track 20-2Clinical Metabolomics
  • Track 20-3Metabolomics in Oncology

Genomic medicine attempts to build individualized strategies for diagnostic or therapeutic decision-making by utilizing patients’ genomic information. Big Data analytics uncovers hidden patterns, unknown correlations, and other insights through examining large-scale various data sets. While integration and manipulation of diverse genomic data and comprehensive electronic health records (EHRs) on a Big Data infrastructure exhibit challenges, they also provide a feasible opportunity to develop an efficient and effective approach to identify clinically actionable genetic variants for individualized diagnosis and therapy. In this paper, we review the challenges of manipulating large-scale next-generation sequencing (NGS) data and diverse clinical data derived from the EHRs for genomic medicine. We introduce possible solutions for different challenges in manipulating, managing, and analyzing genomic and clinical data to implement genomic medicine.

  • Track 21-1Clinically Actionable Genetic Variants
  • Track 21-2Pharmacogenetic Variants
  • Track 21-3Health Informatics
  • Track 21-4Medical Imaging Analysis

Precision medicine aims to tailor treatments based on individual characteristics, including differences in genetics, environment, and lifestyle. It has the potential to transform the delivery of care for a variety of diseases and we are already seeing the benefits of this approach in oncology. To highlight the importance of precision medicine and the key role of diagnostics in ensuring the success of President Obama's Precision Medicine Initiative, the AACR and AdvaMedDx held a congressional briefing featuring some of the top minds across the medical research spectrum, from government agencies, academia, industry, and patient advocacy.

 

  • Track 22-1Medical research spectrum
  • Track 22-2Biomedical discoveries
  • Track 22-3Next generation sequencing (NGS) technologies
  • Track 22-4Product quality and patient safety